Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study.
暂无分享,去创建一个
Philippe Lambin | Geert Bosmans | Dirk De Ruysscher | Angela van Baardwijk | P. Lambin | D. de Ruysscher | M. Hochstenbag | G. Bosmans | A. V. van Baardwijk | R. V. van Suylen | Monique Hochstenbag | G. Geskes | M. V. van Kroonenburgh | Marinus van Kroonenburgh | Robert Jan van Suylen | Gijs Geskes
[1] U. Tateishi,et al. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[2] Michael G. Stabin,et al. Radiation Dose to Patients from Radiopharmaceuticals , 2009 .
[3] Sigrid Stroobants,et al. The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer , 2007 .
[4] V. R. McCready,et al. FDG accumulation and tumor biology. , 1998, Nuclear medicine and biology.
[5] T. Manabe,et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. , 2005, Neoplasia.
[6] Nagara Tamaki,et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] J C Rosenwald,et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. , 2000, International journal of radiation oncology, biology, physics.
[8] Julie Sutcliffe-Goulden,et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] Paul Cumming,et al. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors. , 2005, International journal of radiation oncology, biology, physics.
[10] D. Yan,et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. , 2007, International journal of radiation oncology, biology, physics.
[11] J. Vansteenkiste,et al. Value of FDG-PET in the management of non-small cell lung cancer. , 2003, European journal of radiology.
[12] I. Mellinghoff,et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.
[13] Søren M Bentzen,et al. Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.
[14] Ursula Nestle,et al. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] Philippe Lambin,et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. , 2006, Cancer treatment reviews.
[16] C Clifton Ling,et al. Dependence of FDG uptake on tumor microenvironment. , 2005, International journal of radiation oncology, biology, physics.
[17] R Chan,et al. Computed tomographic-pathologic correlation of gross tumor volume and clinical target volume in non-small cell lung cancer: a pilot experience. , 2001, Archives of pathology & laboratory medicine.